title: Economic evaluations of fluticasone-propionate/salmeterol combination therapy for chronic obstructive pulmonary disease: a review of published studies.
abstract: This review identifies and evaluates the comprehensive reporting of peer-reviewed economic evaluations of the effectiveness of fluticasone-propionate/salmeterol combination (FSC) therapy for maintenance treatment of chronic obstructive pulmonary disease (COPD). Economic evaluations were included if published in English since 2003. Evaluation categories included in the review were cost-effectiveness, cost-utility, and cost-consequence analyses. FSC is cost-effective in comparison to short-acting bronchodilators (SABDs). Cost and outcome differences between FSC and other long-acting therapies were modest. Studies exhibited large variations in populations, designs and environment, limiting the ability to draw conclusions. Many new maintenance treatments for COPD have been approved since 2010. Most have yet to be compared to older treatments like FSC. Evaluations are needed that consider costs and outcomes from a societal perspective (e.g., patients' ability to keep working) and evaluations that include subgroup analyses to investigate differential impacts according to clusters of patient characteristics.
authors.affiliation: a Department of Pharmacy Practice and Administrative Sciences , University of New Mexico College of Pharmacy , Albuquerque , NM , USA.|b LCF Research, Health Services Research Division , Albuquerque , NM , USA.
authors.forename: M H
authors.initials: MH
authors.lastname: Roberts
authors.affiliation: a Department of Pharmacy Practice and Administrative Sciences , University of New Mexico College of Pharmacy , Albuquerque , NM , USA.
authors.forename: M E
authors.initials: ME
authors.lastname: Borrego
authors.affiliation: a Department of Pharmacy Practice and Administrative Sciences , University of New Mexico College of Pharmacy , Albuquerque , NM , USA.
authors.forename: A A
authors.initials: AA
authors.lastname: Kharat
authors.affiliation: a Department of Pharmacy Practice and Administrative Sciences , University of New Mexico College of Pharmacy , Albuquerque , NM , USA.
authors.forename: P L
authors.initials: PL
authors.lastname: Marshik
authors.affiliation: b LCF Research, Health Services Research Division , Albuquerque , NM , USA.
authors.forename: D W
authors.initials: DW
authors.lastname: Mapel
mesh_terms: D001993:Bronchodilator Agents / Q000191:economics / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D000068297:Fluticasone-Salmeterol Drug Combination / Q000191:economics / Q000627:therapeutic use*; D006801:Humans; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy* / Q000191:economics; D016896:Treatment Outcome
chemical_list: D001993:Bronchodilator Agents; D000068297:Fluticasone-Salmeterol Drug Combination
keywords: Bronchodilator agents; CHEERS; QHES; chronic obstructive pulmonary disease; cost-consequence; cost-effectiveness; fluticasone; pharmacoeconomics; review; salmeterol